Ron Hunt is listed as a director on 10 SEC Form D filings by 4 issuers between Mar 2011 and Sep 2024: Harpoon Therapeutics, Inc. (South San Francisco, CA — biotechnology — 2017–2018; $100.2M reported sold to 18 investors), Relypsa Inc (Santa Clara, CA — pharmaceuticals — 2012; $70.1M reported sold to 15 investors), CuraSen Therapeutics, Inc. (San Carlos, CA — biotechnology — 2021–2024; $27.2M reported sold to 11 investors) and KALIDEX PHARMACEUTICALS, INC. (Menlo Park, CA — pharmaceuticals — 2011; $8.25M reported sold to 8 investors).
What this means A repeat sponsor — 4 separate companies raised money with this person listed as director, over about 13 years. Across those companies the filings report $205.8M sold in total.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — 3 bankruptcy cases matching the name listed in Key records below.
What this means 3 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 10 public filings for Ron Hunt and found 10 differences, 1 worth asking the sponsor about: Bankruptcy case: Ron A Hunt and Wilasinee Hunt; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.